New Options for Treatment-Resistant RA
Filgotinib Promising for RA
FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
Simple Tasks
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.
Meeting Abstracts
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
Rheumatology Research Foundation
The Foundation is the largest private funding source for rheumatology research and training in the U.S.